Novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation

A cell-permeable Survivin inhibitor. LLP-3 is an inhibitor of Survivin-Ran complex formation that induces apoptosis in tumor slice cultures, including resistant tumors.

Novel allosteric Pkh inhibitor directed to the PIF-pocket, with increased selectivity for C. albicans Pkh2.

Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively). Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. Decreases prolife

Novel inhibitor of bacterial cell division targeting the GTP binding site of FtsZ

Novel inducer of reactivation of mutant p53 in cancer cells

Novel Inhibitor of Bacterial Transcription Initiation Complex Formation

Novel STAT3 Inhibitor, Inhibiting Cell Viability, Cell Migration, And Angiogenesis in Medulloblastoma Cells

Inhibitor of Ribosome-Inactivating Proteins (RIPs); Blocker of Leishmania parasitophorous vacuoles (LPV) development

Novel inhibitor of the KRS-67LR interaction by directly blocking the association between KRS and 67LR, suppressing the dynamic movement of the N-terminal extension of KRS and reducing membrane localization of KRS

Potent antitumor agent, selectively targeting cancer cells and overcoming tamoxifen resistance

Selective Small-Molecule Inhibitor of Breast Cancer Stem Cells